CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 663 enrolled
Drug / intervention
Indapamide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05103332
NCT05103332Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

Alnylam Pharmaceuticals·interventional·Posted Nov 2, 2021·Updated Nov 3, 2025

In Brief

A Phase 2 clinical trial evaluating Indapamide, Amlodipine, and 3 other interventions for Hypertension. Completed, enrolled 663 participants across 110 sites in 8 countries.

Detailed Summary

The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCanada, Estonia, Germany, Latvia, Lithuania, Poland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedNov 2, 2021
Enrollment StartNov 5, 2021
Primary CompletionDec 11, 2023
Study CompletionSep 13, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.7 years ago

Interventions

Indapamidedrug

Indapamide administered orally

Amlodipinedrug

Amlodipine administered orally

Olmesartandrug

Olmesartan administered orally

Placebodrug

Placebo administered by SC injection

Zilebesirandrug

Zilebesiran administered by SC injection